Equities

Oxford Biomedica PLC

Oxford Biomedica PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)197.20
  • Today's Change0.00 / 0.00%
  • Shares traded101.57k
  • 1 Year change-53.44%
  • Beta1.3331
Data delayed at least 20 minutes, as of Mar 28 2024 14:16 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Key statistics

As of last trade, Oxford Biomedica PLC (OXB:LSE) traded at 197.20, 20.03% above the 52 week low of 164.29 set on Dec 01, 2023.
52-week range
Today
164.29Dec 01 2023474.50Jun 15 2023
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open199.00
High200.00
Low195.00
Bid196.80
Offer199.40
Previous close197.20
Average volume626.21k
Shares outstanding99.96m
Free float80.77m
P/E (TTM)--
Market cap197.12m GBP
EPS (TTM)-0.6389
GBP
Data delayed at least 20 minutes, as of Mar 28 2024 14:16 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Oxford Biomedica PLC shares was Hold at 266.00 on 21 Sep 2023Read the full article

Board of Directors

1/11

Dr. Roch Doliveux, Chairman

2/11

Dr. Frank Mathias, Chief Executive Officer

3/11

Stuart Henderson, Vice Chairman

4/11

Dr. Heather Preston, Independent Non-Executive Director

5/11

Robert Ghenchev, Non-Executive Director

6/11

Dr. Michael Hayden, Non-Executive Director

7/11

Stuart Paynter, Chief Financial Officer

8/11

Professor Dame Kay Davies, Senior Independent Director

9/11

Catherine Moukheibir, Independent Non-Executive Director

10/11

Namrata P Patel, Independent Non-Executive Director

11/11

Leone Patterson, Independent Non-Executive Director

Contact

Headquarters and registered address:
Oxford BioMedica plc
Windrush Court
Transport Way
Oxford
OX4 6LT
United Kingdom

T: +44 (0) 1865 783 000

2023 Interim Results

Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.